# NQMD-CS (five-cancer methylation test in a screening population, Guangzhou)

Source: https://onco.cc/trials/nqmd-cs/  
OnCo record `nqmd-cs` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Chinese study of about 1,250 people testing a blood test for lung, bowel, liver, stomach and gullet cancer in ordinary screening.

## Summary

NQMD-CS (NCT07834268) is a single-arm interventional study sponsored by Fifth Affiliated Hospital of Guangzhou Medical University. It evaluates the feasibility of a cell-free DNA methylation test that gives a binary result and predicts tissue of origin for five cancers.

The registry record, read on 29 October 2026, gives its status as active, not recruiting, with 1,250 participants enrolled, a start on 2 July 2025 and primary completion expected in October 2026.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-10-29
- Also known as: NQMD-CS
- Registry id: NCT07834268
- Phase: not-applicable
- Setting: Adults without symptoms recruited in the community in Guangzhou, given a cell-free DNA methylation test for five cancers with standard screening and one-year follow-up
- Sponsor: Fifth Affiliated Hospital of Guangzhou Medical University
- Enrolled: 1250

## Sources

- ClinicalTrials.gov NCT07834268: https://clinicaltrials.gov/study/NCT07834268

## Connected records

- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)

---
JSON: https://onco.cc/api/v1/entities/nqmd-cs.json